The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Japanese drugmaker Daiichi Sankyo has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective April 1, 2025.

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Daiichi Sankyo appoints Hiroyuki Okuzawa as chief executive officer: Tokyo Saturday, February 1, 2025, 12:30 Hrs [IST] ...

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...

Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as chief executive officer from 1 April 2025.

J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.

Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

U.S. President Donald Trump plans to impose tariffs on imported computer chips, pharmaceuticals and steel, he said on Monday, ...

Analysts fell to the sidelines weighing in on Sumitomo Dainippon Pharma Co (DNPUF – Research Report) and Sanofi (SNYNF – Research Report) with ...

Miki Sogi, an analyst from Bernstein, maintained the Hold rating on Takeda Pharmaceutical Co (TKPHF – Research Report). The associated price ...